MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

A

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

A

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

A

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

A

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

MDT

95.81

+0.14%↑

VEEV

291.64

+2.73%↑

A

145.5

+1.37%↑

HQY

96.5

+3.79%↑

TLRY

1.52

-4.4%↓

Search

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.54 0.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.43

Max

1.55

Põhinäitajad

By Trading Economics

Sissetulek

3.6M

-34M

Müük

278K

1.9M

Kasumimarginaal

-1,786.576

Töötajad

181

EBITDA

979K

-37M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+177.55% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. nov 2025

Turustatistika

By TradingEconomics

Turukapital

53M

160M

Eelmine avamishind

0.89

Eelmine sulgemishind

1.54

Uudiste sentiment

By Acuity

47%

53%

153 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. okt 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20. okt 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

20. okt 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20. okt 2025, 22:14 UTC

Market Talk

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20. okt 2025, 22:00 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20. okt 2025, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20. okt 2025, 20:56 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. okt 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. okt 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20. okt 2025, 20:38 UTC

Tulu

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20. okt 2025, 20:36 UTC

Tulu

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20. okt 2025, 20:16 UTC

Market Talk

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20. okt 2025, 20:05 UTC

Tulu

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20. okt 2025, 19:39 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20. okt 2025, 19:34 UTC

Market Talk

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20. okt 2025, 19:32 UTC

Market Talk

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20. okt 2025, 19:00 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20. okt 2025, 18:29 UTC

Market Talk

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20. okt 2025, 18:11 UTC

Market Talk

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20. okt 2025, 18:04 UTC

Market Talk

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20. okt 2025, 17:03 UTC

Market Talk

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20. okt 2025, 17:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. okt 2025, 17:01 UTC

Market Talk

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20. okt 2025, 16:43 UTC

Market Talk

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20. okt 2025, 16:25 UTC

Market Talk

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

177.55% tõus

12 kuu keskmine prognoos

Keskmine 4.08 USD  177.55%

Kõrge 7 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

3

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

153 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat